IT1208
IT1208 is a humanized anti-CD4 monoclonal IgG1 antibody. IT1208 depletes CD4+ T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Species Reactivity
Human
IC50 & Target
CD4
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human B cell lymphoma Raji cells (1 × 106, i.p.) induced-mice prior to Healthy human peripheral blood mononuclear cells (PBMCs) (20 × 106, i.p.)[2]
-
Dosage:200 μg
-
Administration:i.p., twice a week for 4 weeks
-
Result:Effectively prevented the development of xenogeneic GVHD in mice in experiments using cells from 3 donors.
Exerted only a partial preventive effect on xenogeneic GVHD in mice in the experiment using cells from 1 single donor.
Significantly prevented GVHD-associated damage to target tissues including the skin, salivary glands, liver and lung in mice.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Shitara K, et al., Matsushima K, Doi T. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. J Immunother Cancer. 2019 Jul 24;7(1):195. [Content Brief]
[2]. Liu M, Yang J, Xu B, Zhang X. Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm (2020). 2021 Dec 2;2(4):587-617. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)